Conventional treatments for eye diseases such as Glaucoma and Dry Eye Disease are insufficient- they require frequent dosing (multiple times a day for some meds), can be painful to dose and patient compliance can be as low as 50%. The goal of 20/20 OptimEyes Technologies is to use our proprietary micelle platform technology to better control the release of drugs. This will allow for prolonged drug penetration into the eye, meaning patients can use a comfortable drop only once or twice per week.
Company Details
- Employees
- 3
- Founded
- 2018
- Address
- 1280 Main St W, Hamilton,ontario L8s 4k1,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://2020optimeyes.ca
- Keywords
- Drug Delivery and Ophthalmology.
- HQ
- Hamilton, Ontario
20/20 Optimeyes Technologies Questions
20/20 Optimeyes Technologies's website is http://2020optimeyes.ca
20/20 Optimeyes Technologies's LinkedIn profile is https://ca.linkedin.com/company/20-20-optimeyes
20/20 Optimeyes Technologies has
3 employees.
View email and phone details for 3
employees at 20/20 Optimeyes Technologies.
20/20 Optimeyes Technologies's industry is
Biotechnology Research
20/20 Optimeyes Technologies's top competitors are
Zucara Therapeutics Inc.,
Able Innovations,
Spiderwort Biotechnologies Inc.,
Histone Therapeutics,
Paradox Immunotherapeutics,
Proteinqure,
Rocket Doctor,
Ripple Therapeutics,
Noa Therapeutics,
Diamond Therapeutics.
20/20 Optimeyes Technologies's categories are Biotechnology Research
20/20 Optimeyes Technologies's founding year is 2018
